Which medication acts as an Interleukin-5 receptor antagonist for individuals 6 years or older?

The medication that acts as an Interleukin-5 receptor antagonist for individuals 6 years or older is Mepolizumab. This drug is specifically designed to target and inhibit interleukin-5 (IL-5), a cytokine that plays a critical role in the growth and activation of eosinophils, which are white blood cells involved in inflammatory responses, particularly in conditions like asthma and eosinophilic granulomatosis with polyangiitis. By blocking the IL-5 receptor, Mepolizumab reduces eosinophil levels in the blood and tissues, thereby helping to decrease inflammation and improve asthma control in patients.

Other options such as Omalizumab, Fluticasone, and Montelukast serve different purposes in managing respiratory conditions, but they do not function as IL-5 receptor antagonists. Omalizumab is an anti-IgE antibody, Fluticasone is an inhaled corticosteroid that reduces inflammation, and Montelukast is a leukotriene receptor antagonist used to control asthma and allergic rhinitis. Each of these medications plays a unique role in management strategies, but for specifically targeting IL-5, Mepolizumab is the appropriate choice.